The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study

Mato, AR; Sharman, JP; Biondo, JML; Wu, M; Mun, Y; Kim, SY; Humphrey, K; Boyer, M; Zhu, Q; Seymour, JF

Author(s): Mato, AR; Sharman, JP; Biondo, JML; Wu, M; Mun, Y; Kim, SY; Humphrey, K; Boyer, M; Zhu, Q; Seymour, JF;
Details: Publication Year 2022-01-01,Volume 107,Issue #1,Page 134-142
Journal Title: Haematologica
Publication Type: Research article
Abstract: Fixed-duration venetoclax plus rituximab (VenR) has a manageable safety profile and improves survival in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). We present data from the phase III MURANO study on the impact of venetoclax modification or premature discontinuation on outcomes in patients with R/R CLL. Time-dependent Cox proportional hazards regression models, stratified by 17p deletion and risk status, evaluated the impact of venetoclax discontinuation/modification on investigator-assessed progression-free survival (PFS) and overall survival (OS). Analyses were performed retrospectively (without type-1 error control) in intention-to-treat patients from the VenR arm of MURANO. Overall, 140/194 (72%) patients in the VenR arm completed 2 years of therapy; 54/194 (28%) patients prematurely discontinued treatment. Inferior PFS was observed in patients prematurely discontinuing venetoclax for any reason (disease progression excluded; p.
Keywords: *Antineoplastic Agents/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use; Humans; *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Retrospective Studies; Sulfonamides
Department(s): Haematology
PubMed ID: 33327712
Publisher's Version: https://doi.org/10.3324/haematol.2020.266486
Open Access at Publisher's Site: https://doi.org/10.3324/haematol.2020.266486
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-01-31 03:38:59

Last Modified: 2025-01-31 03:40:50